In particular, the fact that prostate cancer stem cells (CD44+/CD133+/α2β1+) share antigenic properties with prostate stem cells (CD133+/α2β1+) supports the idea that they arise from the normal stem/progenitor cell counterpart [29–31]. This evidence concerns the gene PROM1 and prostate carcinoma.